Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Stopped early · Phase 3
Conditions studied: Lymphoma
In brief
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase III trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00004874
- Run by
- University of Nebraska
- People needed
- 31
- Starts
- 1998-11-01
- Expected to finish
- 2012-11-01
- Last updated by the study team
- 2018-01-17
Who can join
Age: 19 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Nebraska Medical Center — Omaha, Nebraska, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.